Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Amarin Stock Plunged in February

TheMotleyFool

0 0

Shares of mid-cap drugmaker Amarin (NASDAQ: AMRN) fell by 20.9% in February, according to data from S&P Global Market Intelligence.

The Irish biopharma hit the skids last month for two reasons.

First, investors apparently weren't entirely enthused with Amarin's fourth-quarter results released on Feb. 25. Even though the company beat Wall Street's consensus revenue figure for the three-month period by a healthy 4%, Amarin's shareholders were hoping to get an updated annual guidance to the upside. Unfortunately, the company simply maintained its 2020 annual guidance when it reported fourth-quarter results, calling for net total revenue of between $650 million to $700 million for the full year.

Source Fool.com

Like: 0

AMRN

Share